(RTTNews) - MeiraGTx Holdings plc (MGTX), a vertically integrated, clinical-stage genetic medicines company, announced Tuesday positive top-line data from MGT-GAD-025, its clinical bridging study of ...
On Tuesday, MeiraGTx Holdings plc (NASDAQ:MGTX) released topline data from its clinical bridging study of AAV-GAD for Parkinson’s disease, MGT-GAD-025. MGT-GAD-025 is a 6-month, three-arm, randomized, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback